We would love to hear your thoughts about our site and services, please take our survey here.
This is how they used to do:
Jamnes Simpson, together with his assistants were in the habit of experimenting with chemicals in his dining room to see whether they had any anaesthetic effect. On the evening of 4 November 1847, they tried chloroform, a substance they had previously ignored as unpromising. The immediately effect was elation followed by a sudden loss of consciousness. On coming round the following morning, Simpson knew that he had found a substance that he could use as a general anaesthetic. He repeated the experiment on his niece with the same effect. He began to employ chloroform in childbirth on 8 November 1847 and described its uses in a pamphlet Account of a New Anaesthetic Agent. Within weeks of its appearance, chloroform had almost completely replaced ether as the standard anaesthetic.
Come on Avacta!
54retiresoon - The path to remaining independent is for Avacta to continue licensing deals with multiple big Pharma companies across the spectrum.
I agree, It is worth comparing AVCT with ARM - and their IPR licensing model - they remained independent for some 20+ years after listing and were eventually bought, for what, ÂŁ7bn?
Oops meant to put this here - AS may already have had tentative approaches from companies seeking to license AVA6000 - subject to confirmation of the expected good P1 DE results mid-year?
Presumably AS may already have had tentative approaches from companies seeking to license AVA6000 - subject to confirmation of the expected good P1 DE results mid-year?
And its fair to say its so true!
Hi TTB, have AVCT said at any point how many DE steps they might make in P1A?
Thanks Mr A. From the pov of an individual patient in a trial that appeared to be giving me new hope, I would certainly want every opportunity to volunteer for a further 'escalation' of my treatment. And if the AVA6000 programme is going so well. it would seem perverse if Avacta's Safety Monitoring Committee and the MHRA or whoever failed to accelerate it - greatly expand the number of patients involved. etc. But then all this is totally outside of my field of knowlegdge!
Re what you say Wiggly about it not being ethical to carry on when no improvement is seen... is there ever the opposite case in trials like these when it becomes obvious that a treatment is extremely successful, to such an extent that it is unethical not to accelerate approval and use?
Well pleased with all of that.
Best wishes from me too Poirot - on my occasional forays here your posts are amongst the sadly too few standouts. Looking forward to your return
Thanks Stodgy, that was in the final, busiest week during my six months of upheaval - now thankfully all over! Its not surprising I missed it! Very interesting. And that the story is being picked up in the Telegraph today is interesting too.
Much as I would have liked to, for the last six months or so I've not had the time to keep up with all the sleuthing, the news unearthed here about Avacta - and the follow up discussion. I still hold shares though and in the last week or so have dipped in occasionally. In this thread these snippets have caught my eye:
"Medusa19 beat some major diagnostics companies to self test approval in Europe... " "We only just have HUA give it time for them to finalise contracts."
Could some kind soul point to where / when this was announced / unearthed. Has AVCT confirmed HUA approval in Europe.
I imagine there must have been extensive discusssion on here when all was revealed? Roughly when would this have been - so I can attempt a search back?
One of the statistics I read recently was that the average age of those currently being recorded as dying within 28 days of positive COVID test is 85 and that on average each had 5 comorbidities - other conditions and circumstances which make them vulnerable. These are people dying with Covid and not necessarily of it. I am in my late seventies and at my stage in life it does cross ones mind that one might pop ones clogs fairly soon! During one of the Downing Street press conferences in the first lockdown Van Tam made what I thought was a most ludicrous remark. He said we can't let our old people die. What are old people supposed to do for goodness sake.
Thanks doze - I've not been following posts on this board anywhere near as closely as I once did and missed this. FDH
I read earlier that this was released over the weekend? Could someone kindly point me to where I can take a look at this. Thanks
Thx PL75, trust me to get it the wrong way around!
The remark AS made about continuing to test negatives to drive thr decimal point was interesting. I believe I am right in saying the better the sensitivity (99% in the original CV?) the fewer the false negatives there will be. Which again if I've got it right, will make AVCT's LFD even better for 'green-lighting.' And the ability to use a test for 'green-lighting' is exactly what airlines and others looking to introduce high quality fast cheap daily sel-testing to keep staff Covid clear will be after. False negatives are the last thing you want in situations where an outbreak amongst staff can critically affect operations. So a good pointer to the sort of use case and differentiator AS expects to derive from having one of (or even the best) test availabale, once validated for self-testing. (I think my thinking is properly thought through?)
I am sure that AVCT are seeking ISO certification. It will be for the chemical processes used in the manufacture of affimers.
Good time to bury adverse reports and reassure that us the UK gov has every confidence in the lateral flow tests used by our NHS?
The cynic in me very much goes along with PL - 10.24 am. But the logic (or illogic) in the mess the UK government seems to be getting into is that goodwill toward it amongst UK diagnostic businesses will be so low they will sell all they can produce elsewhere. Following this argument production capacity might never become sufficient to adequately replace Innova (or cheap Innova clones) with affimer based "sovereign LFDs". Other than at a hefty pemium? The again the cynic in me thinks they prefer the brown envelope approach to paying any sort of premium.